Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia

被引:13
|
作者
De Nunzio, Cosimo [1 ]
Giglio, Simona [2 ]
Stoppacciaro, Antonella [2 ]
Gacci, Mauro [4 ]
Cirombella, Roberto [2 ]
Luciani, Emidio [2 ]
Tubaro, Andrea [1 ]
Vecchione, Andrea [2 ,3 ]
机构
[1] Sapienza Univ, Osped St Andrea, Dept Clin & Mol Med, Urol Units, Rome, Italy
[2] Sapienza Univ, Osped St Andrea, Dept Clin & Mol Med, Surg Pathol Units, Rome, Italy
[3] Ohio State Univ, CCC, Dept Canc Biol & Genet, Columbus, OH 43210 USA
[4] Careggi Hosp, Dept Urol, Florence, Italy
关键词
autophagy; BPH; LUTS; inflammation; prostate; METABOLIC SYNDROME; REGULATES INFLAMMATION; PATHOGENESIS; OBESITY;
D O I
10.18632/oncotarget.15144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Autophagy is a conserved evolutionary process that allows cells to maintain macromolecular synthesis and energy homeostasis during starvation and stressful conditions. We prospectively evaluated the relationship between autophagy and prostatic inflammation in a series of transurethral prostatic resection samples. Inflammatory infiltrates were defined according to the standardized classification of chronic prostatitis of the National Institute of Health. The inflammatory score (IS score) was calculated. High IS score was defined as >= 7. Each sample was stained for anti-LC3B and for anti-P62/SQSTM1 and scored. High p62 or LC3B percentage was defined as > 25%, whereas low was defined as < 25% of cells with dots. We analyzed 94 specimens. Overall, 18/94 (19%) showed no sign of prostatic inflammation, whereas 76/94 (81%) presented inflammatory infiltrates. Inflammation was mild in 61/76 (80%), moderate/severe in 15/76 (20%). Patients with high p62 percentage were 62/94 (66%) while 32 (34%) showed low p62 percentage. Patients with high LC3B percentage were 37/94 (39%) while 57(61%) showed low LC3B percentage. Overall 42/94 (44%) patients presented a high p62 percentage and concomitant a low LC3B percentage. IS score was significantly higher in patients with a with high p62 percentage (median IS 7 (6/8) vs 5 (3/7); p=0.04) and in patients with a low LC3B percentage (median IS 7 (6/8) vs 5 (3/7); p=0.004) when compared to patients with a low p62 percentage or a high LC3B percentage respectively. On multivariate analysis, p62 (OR: 10.1, 95% CI: 2.6-38.6; p=0,001) and LC3B expression (OR: 0.319; 95% CI: 0.112-0.907; p=0.032) were independent predictors of a high IS. Here we present the first evidence of autophagy deregulation in prostatic inflammation. These results raise many questions about the mechanisms mediating the autophagy dysfunction and the links to prostatic inflammation that need to be addressed.
引用
收藏
页码:50904 / 50910
页数:7
相关论文
共 50 条
  • [31] Physical Activity And Benign Prostatic Hyperplasia / Lower Urinary Tract Symptoms
    Wolin, Kathleen Y.
    Grubb, Robert, III
    Pakpahan, Ratna
    Ragard, Lawrence
    Mabie, Jerome
    Andriole, Gerald
    Sutcliffe, Siobhan
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2013, 45 (05): : 261 - 261
  • [32] Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia
    Wiser H.J.
    Köhler T.S.
    Current Urology Reports, 2010, 11 (4) : 228 - 235
  • [33] NATIONAL SURGICAL TRENDS IN LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Welliver, Charles
    Feinstein, Lydia
    Ward, Julia B.
    Abbott, Kevin C.
    Bavendam, Tamara
    Kirkali, Ziya
    Martinez-Miller, Erline
    Matlaga, Brian R.
    McVary, Kevin
    JOURNAL OF UROLOGY, 2020, 203 : E1188 - E1189
  • [34] EVOLUTION OF HEALTHCARE COSTS FOR LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Welliver, Charles
    Ward, Julia B.
    Feinstein, Lydia
    Abbott, Kevin C.
    Bavendam, Tamara
    Kirkali, Ziya
    Martinez-Miller, Erline
    Matlaga, Brian R.
    McVary, Kevin
    JOURNAL OF UROLOGY, 2020, 203 : E619 - E619
  • [35] National Trends in the Management of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
    Joseph T. Mahon
    Charles Welliver
    Current Urology Reports, 2020, 21
  • [36] Evolution of healthcare costs for lower urinary tract symptoms associated with benign prostatic hyperplasia
    Charles Welliver
    Lydia Feinstein
    Julia B. Ward
    Ziya Kirkali
    Erline Martinez-Miller
    Brian R. Matlaga
    Kevin McVary
    International Urology and Nephrology, 2022, 54 : 2797 - 2803
  • [37] Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome
    Vignozzi, Linda
    Gacci, Mauro
    Maggi, Mario
    NATURE REVIEWS UROLOGY, 2016, 13 (02) : 108 - 119
  • [38] UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia
    Eardley, Ian
    BJU INTERNATIONAL, 2021, 128 (03) : 270 - 270
  • [39] Treatment of Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia Foreword
    Taneja, Samir S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2016, 43 (03) : XIII - XIV
  • [40] The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis
    Nickel, JC
    CURRENT OPINION IN UROLOGY, 2006, 16 (01) : 5 - 10